Journal article
V. Phan, Mohanapriya Murugesan, P. Manivasagan, Thanh Loc Nguyen, Thuy-Hien Phan, Cuong Hung Luu, Duy‐Khiet Ho, Yi Li, Jaeyun Kim, D. S. Lee, Thavasyappan Thambi
Pharmaceutics, 2022
Pharmaceutics, 2022
Semantic Scholar
DOI
PubMedCentral
PubMed
Cite
Cite
APA
Click to copy
Phan, V., Murugesan, M., Manivasagan, P., Nguyen, T. L., Phan, T.-H., Luu, C. H., … Thambi, T. (2022). Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment. Pharmaceutics.
Chicago/Turabian
Click to copy
Phan, V., Mohanapriya Murugesan, P. Manivasagan, Thanh Loc Nguyen, Thuy-Hien Phan, Cuong Hung Luu, Duy‐Khiet Ho, et al. “Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment.” Pharmaceutics (2022).
MLA
Click to copy
Phan, V., et al. “Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment.” Pharmaceutics, 2022.
BibTeX Click to copy
@article{v2022a,
title = {Injectable Hydrogel Based on Protein-Polyester Microporous Network as an Implantable Niche for Active Cell Recruitment},
year = {2022},
journal = {Pharmaceutics},
author = {Phan, V. and Murugesan, Mohanapriya and Manivasagan, P. and Nguyen, Thanh Loc and Phan, Thuy-Hien and Luu, Cuong Hung and Ho, Duy‐Khiet and Li, Yi and Kim, Jaeyun and Lee, D. S. and Thambi, Thavasyappan}
}
Abstract
Despite the potential of hydrogel-based localized cancer therapies, their efficacy can be limited by cancer recurrence. Therefore, it is of great significance to develop a hydrogel system that can provoke robust and durable immune response in the human body. This study has developed an injectable protein-polymer-based porous hydrogel network composed of lysozyme and poly(ε-caprolactone-co-lactide)-b-poly(ethylene glycol)-b-poly(ε-caprolactone-co-lactide (PCLA) (Lys-PCLA) bioconjugate for the active recruitment dendritic cells (DCs). The Lys-PCLA bioconjugates are prepared using thiol-ene reaction between thiolated lysozyme (Lys-SH) and acrylated PCLA (PCLA-Ac). The free-flowing Lys-PCLA bioconjugate sols at low temperature transformed to immovable gel at the physiological condition and exhibited stability upon dilution with buffers. According to the in vitro toxicity test, the Lys-PCLA bioconjugate and PCLA copolymer were non-toxic to RAW 263.7 cells at higher concentrations (1000 µg/mL). In addition, subcutaneous administration of Lys-PCLA bioconjugate sols formed stable hydrogel depot instantly, which suggested the in situ gel forming ability of the bioconjugate. Moreover, the Lys-PCLA bioconjugate hydrogel depot formed at the interface between subcutaneous tissue and dermis layers allowed the active migration and recruitment of DCs. As suggested by these results, the in-situ forming injectable Lys-PCLA bioconjugate hydrogel depot may serve as an implantable immune niche for the recruitment and modification of DCs.